CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 10/04/2026 BST			5-day change	1st Jan Change
175.65 ^USD	+0.06%		+1.01%	-11.95%

04-08	Baird Raises Price Target on Charles River Laboratories International to $200 From $197, Maintains Outperform Rating	MT
03-31	AI-led selloff in contract research firms may be misjudging disruption risk	RE

Highlights

03-31	AI-led selloff in contract research firms may be misjudging disruption risk	RE
03-12	Locus Cell Co., Ltd. And Charles River Laboratories Sign Memorandum Of Understanding For Cell And Gene Therapy Collaboration	CI
03-05	Therna Biosciences, Inc. Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics	CI
02-25	IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE : CRL) for $155 million.	CI
02-25	GI Manager L.P. signed a definitive agreement to acquire Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI
02-25	Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated	MT
02-25	Charles River raises annual profit view as it sells underperforming assets	RE
02-25	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
02-25	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30	MT
02-18	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
02-18	Charles River Laboratories International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 27, 2025	CI
02-18	Charles River Laboratories International, Inc. Announces Executive Appointments	CI
02-18	Charles River forecasts upbeat 2026 profit on improved demand for drug development services	RE
02-18	Charles River Laboratories International, Inc. Provides Earnings Guidance for the Year 2026	CI
02-18	Charles River Q4 Adjusted Earnings, Revenue Decline; New CFO Named	MT
02-18	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $10.70 - $11.20, vs. FactSet Est of $11	MT
02-18	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q4 Revenue $994.2M, vs. FactSet Est of $987.0M	MT
02-18	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q4 Adjusted EPS $2.39 per Share, vs. FactSet Est of $2.35	MT
01-21	Charles River Laboratories International, Inc. Enters Manufacturing Collaboration with Gazi University	CI
01-21	When America Starts to Feel Like a Risky Asset
01-21	Charles River Enters Into Manufacturing Collaboration With Gazi University	MT
01-20	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
01-13	Charles River Laboratories International Seeks Acquisitions	CI
01-12	Charles River Laboratories Reports Two Planned Acquisitions; Names Namandje Bumpus as Chief Scientific and Innovation Officer	MT
01-12	Charles River to buy Cambodia-based monkey supplier for $510 million	RE